Pathogenesis of antiphospholipid syndrome: Understanding the antibodies

Nature Reviews Rheumatology

Volumn 7, Issue 6, 2011, Pages 330-339

  Meroni, Pier Luigi ^a   Borghi, M Orietta ^b   Raschi, Elena ^b   Tedesco, Francesco ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E RECEPTOR 2; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOCORTIN 2; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 8; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PROTHROMBIN; PROTHROMBIN ANTIBODY; THROMBOPLASTIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL CLASSIFICATION; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; DECIDUA; ENDOTHELIUM CELL; FETUS WASTAGE; HUMAN; INNATE IMMUNITY; INTRACELLULAR SIGNALING; NONHUMAN; PATHOGENESIS; PLACENTA; PLACENTAL THROMBOSIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOGENESIS; THROMBOSIS; TROPHOBLAST;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 79958086576     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.52     Document Type: Review

References (93)

1. Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295-306 (2006).
2. Giannakopoulos, B., Passam, F., Rahgozar, S. & Krilis, S. A. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109, 422-430 (2007). (Pubitemid 46105935)
3. Pierangeli, S. S. et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin. Thromb. Hemost. 34, 236-250 (2008).
4. De Laat, B., Mertens, K. & De Groot. P. G. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat. Clin. Pract. Rheumatol. 4, 192-199 (2008).
5. Krone, K. A., Allen, K. L. & McCrae, K. R. Impaired fibrinolysis in the antiphospholipid syndrome. Curr. Rheumatol. Rep. 12, 53-57 (2010).
6. Shoenfeld, Y., Meroni, P. L. & Toubi, E. Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale? Curr. Opin. Rheumatol. 21, 495-500 (2009).
7. Katzav, A., Shoenfeld, Y. & Chapman, J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 38, 196-200 (2010).
8. 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 94, 1746-1751 (1996). (Pubitemid 26320284)
9. 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 101, 157-162 (2003). (Pubitemid 36025902)
10. 2GPI and apoER2. J. Clin. Invest. 121, 120-131 (2011).
11. 2-glycoprotein I is complement dependent and requires a priming factor. Blood 106, 2340-2346 (2005). (Pubitemid 41510805)
12. Espinola, R. G. et al. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J. Thromb. Haemost. 1, 843-848 (2003).
13. Vega-Ostertag, M. E. et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J. Thromb. Haemost. 5, 1828-1834 (2007). (Pubitemid 47288938)
14. Romay-Penabad, Z. et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 117, 1408-1414 (2010).
15. Pierangeli, S. S. et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann. Rheum. Dis. 66, 1327-1333 (2007). (Pubitemid 47492476)
16. 2-glycoprotein autoantibodies. J. Thromb. Haemost. 9, 149-153 (2011).
17. Vega-Ostertag, M., Liu, X., Kwan-Ki, H., Chen, P. & Pierangeli, S. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br. J. Haematol. 135, 214-219 (2006). (Pubitemid 44401619)
18. Chen, P. P. & Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr. Rheumatol. Rep. 12, 45-52 (2010).
19. Atsumi, T. et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 43, 1982-1993 (2000).
20. Bertolaccini, M. L., Atsumi, T., Koike, T., Hughes, G. R. & Khamashta, M. A. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb. Haemost. 93, 289-297 (2005). (Pubitemid 40253734)
21. 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102, 2717-2723 (2003). (Pubitemid 37248837)
22. Galli, M. et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 110, 1178-1183 (2007). (Pubitemid 47281414)
23. Meroni, P. L. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J. Autoimmun. 30, 99-103 (2008).
24. 2- glycoprotein I and preserved during species' evolution. J. Immunol. 157, 5732-5738 (1996). (Pubitemid 126448998)
25. Nevinsky, G. A. & Buneva, V. N. Natural catalytic antibodies in norm, autoimmune, viral, and bacterial diseases. ScientificWorldJournal 10, 1203-1233 (2010).
26. Yang, Y. H. et al. Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity. Rheumatology (Oxford) 49, 34-42 (2010).
27. 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood 116, 1995-1997 (2010).
28. Meroni, P. L. et al. Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus 19, 453-456 (2010).
29. Peaceman, A. M. & Rehnberg, K. A. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production. Am. J. Obstet. Gynecol. 169, 1403-1406 (1993). (Pubitemid 24009168)
30. Nayar R. & Lage J. M. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum. Pathol. 27, 201-206 (1996). (Pubitemid 26049477)
31. Rand, J. H., Wu, X. X., Quinn, A. S. & Taatjes, D. J. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 19, 460-469 (2010).
32. Rand, J. H. et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am. J. Obstet. Gynecol. 171, 1566-1572 (1994).
33. Park, A. L. in Hughes' Syndrome (ed. Khamashta, M. A.) Ch. 28 Placental pathology in antiphospholipid syndrome, 362-374 (Springer-Verlag, London, 2006).
34. Chaouat, G. The Th1/Th2 paradigm: still important in pregnancy? Semin. Immunopathol. 29, 95-113 (2007). (Pubitemid 47603024)
35. Holers, V. M. et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 195, 211-220 (2002).
36. Girardi, G. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112, 1644-1654 (2003). (Pubitemid 38063722)
37. Berman, J., Girardi, G. & Salmon, J. E. TNF-á is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J. Immunol. 174, 485-490 (2005). (Pubitemid 40007438)
38. Thurman, J. M. et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol. Immunol. 42, 87-97 (2005). (Pubitemid 39360930)
39. Girardi, G., Yarilin, D., Thurman, J. M., Holers, V. M. & Salmon, J. E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203, 2165-2175 (2006). (Pubitemid 44352237)
40. Redecha, P. et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110, 2423-2431 (2007). (Pubitemid 47523163)
41. Redecha, P., Franzke, C. W., Ruf, W., Mackman, N. & Girardi, G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J. Clin. Invest. 118, 3453-3461 (2008).
42. Seshan, S. V. et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 114, 1675-1683 (2009).
43. Girardi, G., Redecha, P. & Salmon, J. E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10, 1222-1226 (2004). (Pubitemid 39540439)
44. Martinez De la Torre, Y. et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc. Natl Acad. Sci. USA 104, 2319-2324 (2007).
45. Cowchock, F. S., Reece, E. A., Balaban, D., Branch, D. W. & Plouffe, L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am. J. Obstet. Gynecol. 166, 1318-1323 (1992).
46. Ruiz-Irastorza, G., Crowther, M., Branch, W. & Khamashta, M. A. Antiphospholipid syndrome. Lancet 376, 1498-1509 (2010).
47. Shamonki, J. M., Salmon, J. E., Hyjek, E. & Baergen, R. N. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 196, e1-e5 (2007).
48. Cavazzana, I. et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J. Autoimmun. 28, 160-164 (2007). (Pubitemid 46680500)
49. Gerosa, M. et al. Complement involvement in antiphospholipid-mediated placental damage: prospective study in APS pregnant women [abstract THU0120] Ann. Rheum. Dis. 68 (Suppl. 3), 210 (2009).
50. 2GPI PL-binding site [abstract 644]. Arthritis Rheum. 58, S404 (2008).
51. Francis, J. et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol. Hum. Reprod. 12, 435-442 (2006). (Pubitemid 44288202)
52. Borghi, M. O. et al. Antiphospholipid antibodies reactivity with human decidual cells: an additional mechanism of pregnancy complications in APS and a potential target for innovative therapeutic intervention [abstract OP-0119]. Ann. Rheum. Dis. 68 (Suppl. 3), 109 (2009).
53. 2-glycoprotein I antibodies in vitro. Ann. Rheum. Dis. 64, 462-467 (2005). (Pubitemid 40283060)
54. 2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 15, 358-365 (2006). (Pubitemid 44032711)
55. Tincani, A., Rebaioli, C. B., Andreoli, L., Lojacono, A. & Motta, M. Neonatal effects of maternal antiphospholipid syndrome. Curr. Rheumatol. Rep. 11, 70-76 (2009).
56. Renaudineau, Y., Dugué, C., Dueymes, M. & Youinou, P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun. Rev. 1, 365-372 (2002). (Pubitemid 38340250)
57. 2-glycoprotein I. J. Immunol. 185, 1550-1557 (2010).
58. Raschi, E. et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101, 3495-3500 (2003). (Pubitemid 36857933)
59. Cockrell, E., Espinola, R. G. & McCrae, K. R. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus 17, 943-951 (2008).
60. Wegrowski, Y. et al. Cell surface proteoglycan expression during maturation of human monocytes-derived dendritic cells and macrophages. Clin. Exp. Immunol. 144, 485-493 (2006). (Pubitemid 43799932)
61. Lambrianides, A. et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J. Immunol. 184, 6622-6628 (2010).
62. Yang, X. V. et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc. Natl Acad. Sci. USA 106, 274-279 (2009).
63. 2 GPI-induced tissue factor expression on monocytes. Int. J. Mol. Med. 24, 557-562 (2009).
64. Kaneider, N. C. et al. Expression and function of syndecan-4 in human platelets. Thromb. Haemost. 93, 1120-1127 (2005). (Pubitemid 40823518)
65. Cognasse, F. et al. Evidence of Toll-like receptor molecules on human platelets. Immunol. Cell Biol. 83, 196-198 (2005). (Pubitemid 40469328)
66. 2-glycoprotein I requires signaling via both glycoprotein Ibá and apolipoprotein E receptor 2'. J. Thromb. Haemost. 6, 1405-1412 (2008). (Pubitemid 352016322)
67. Chen, C. P., Liu, S. H., Lee, M. Y. & Chen, Y. Y. Heparan sulfate proteoglycans in the basement membranes of the human placenta and decidua. Placenta 4, 309-316 (2008).
68. Koga, K. & Mor, G. Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy disorders. Am. J. Reprod. Immunol. 63, 587-600 (2010).
69. Mulla, M. J. et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am. J. Reprod. Immunol. 62, 96-111 (2009).
70. Hoang, V. M. et al. Functional proteomics: examining the effects of hypoxia on the cytotrophoblast protein repertoire. Biochemistry 40, 4077-4086 (2001). (Pubitemid 32280445)
71. Abaskharoun, M., Bellemare, M., Lau, E. & Margolis, R. U. Glypican-1, phosphacan/ receptor protein-tyrosine phosphatase-æ/â and its ligand, tenascin-C, are expressed by neural stem cells and neural cells derived from embryonic stem cells. ASN Neuro. 2, e00039 (2010).
72. Tang, S. C. et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc. Natl Acad. Sci. USA 104, 13798-13803 (2007).
73. Myant, N. B. Reelin and apolipoprotein E receptor 2 in the embryonic and mature brain: effects of an evolutionary change in the apoER2 gene. Proc. Biol. Sci. 277, 345-351 (2010).
74. Chua, C. C., Rahimi, N., Forsten-Williams, K. & Nugent, M. A. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ. Res. 94, 316-323 (2004). (Pubitemid 38240722)
75. Satta, N. et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 109, 1507-1514 (2007). (Pubitemid 46239583)
76. Romay-Penabad, Z. et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 114, 3074-3083 (2009).
77. Raschi, E., Broggini, V., Borghi, M. O., Grossi, C. & Meroni, P. L. TLR-4 and Annexin A2 involvement in endothelial cell activation by anti-phospholipid antibodies: specific silencing by small interfering RNAs [abstract 1356]. Arthritis Rheum. 62 (Suppl.), S563 (2010).
78. 2 glycoprotein I antibodies. Blood 105, 1964-1969 (2005). (Pubitemid 40731779)
79. 2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J. Clin. Immunol. 23, 377-383 (2003). (Pubitemid 37083192)
80. 2-glycoprotein I and thrombosis: an international multicenter study. J. Thromb. Haemost. 7, 1767-1773 (2009).
81. 2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome. Lupus 19, 400-405 (2010).
82. 2-glycoprotein I: proof of concept. J. Thromb. Haemost. 7, 833-842 (2009).
83. Shoenfeld, Y. et al. Infectious origin of the antiphospholipid syndrome. Ann. Rheum. Dis. 65, 2-6 (2006). (Pubitemid 41815631)
84. 2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 116, 1336-1343 (2010).
85. 2GPI minibody isolated from human phage display library [abstract A006]. Lupus 19, 497-498 (2010).
86. McIntyre, J. A., Wagenknecht, D. R. & Sugi, T. Phospholipid binding plasma proteins required for antiphospholipid antibody detection -an overview. Am. J. Reprod. Immunol. 37, 101-110 (1997). (Pubitemid 27075974)
87. 2 Glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J. Rheumatol. 21, 1684-1693 (1994). (Pubitemid 24285484)
88. Pierangeli, S. S. et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 52, 2120-2124 (2005). (Pubitemid 40994335)
89. Munakata, Y. et al. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb. Haemost. 83, 728-731 (2000). (Pubitemid 30248522)
90. Oku, K. et al. Complement activation in patients with primary antiphospholipid syndrome. Ann. Rheum. Dis. 68, 1030-1035 (2009).
91. Ziglioli, T. et al. Low complement levels during pregnancy are associated with obstetric complications in patients with primary antiphospholipid syndrome [abstract THU0129]. Ann. Rheum. Dis. 68 (Suppl. 3), 213-214 (2009).
92. Tedesco, F. et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 185, 1619-1627 (1997). (Pubitemid 27203258)
93. Girardi, G. Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 39, 160-165 (2010).